What question did this study set out to answer?

August 9, 2006Lara D. Veeken

Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis

View Full Paper

Ask AI

Bookmark

Authors

SNSvetlana I. NihtyanovaBritish Society for Rheumatology GBGeraldine BroughBritish Society for Rheumatology CBC. M. BlackJacksonville College

Discussion

Member takes

Implication

Retrospective analysis shows tolerability and effectiveness of mycophenolate mofetil in patients with diffuse cutaneous systemic sclerosis, suggesting further study is needed.

Key Points

Assess the use and effects of mycophenolate mofetil in patients with diffuse cutaneous systemic sclerosis.
Reviewed clinical records of 109 patients treated with mycophenolate mofetil and 63 control subjects.
Collected data over a 5-year period from treatment initiation until last assessment date.
12% of MMF patients experienced adverse reactions, mainly gastrointestinal disturbances and infections.
MMF-treated cohort had significantly lower frequency of clinically significant pulmonary fibrosis (P=0.037).
Significantly better 5-year survival from disease onset (P=0.027) and from commencement of treatment (P=0.012).

Cite This Study

Nihtyanova et al. (2006) studied this question.

synapsesocial.com/papers/6a638759809dd4a9e2c1e4ea https://doi.org/10.1093/rheumatology/kel244

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows tolerability and effectiveness of mycophenolate mofetil in patients with diffuse cutaneous systemic sclerosis, suggesting further study is needed.

Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider